Ranking Invest

Beam Therapeutics Inc.

Segmento: Healthcare Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Indicadores Básicos

Valor de Mercado

$ 1.65 Bi

IVR

0.13

IVR2

-0.57

Índices de Previsibilidade

Faturamento

0.54

Lucro

0.20

Margem

0.78

Índices de Tendência

Faturamento

0.53

Lucro

-8.58

Margem

2.44

Índices de Endividamento

DIV/PAT

-0.33

DIV/L4T

0.95

Dívida Líquida

-$ 369.78 Mi

Patrimônio Líquido

$ 1.12 Bi

L4T

-$ 387.34 Mi

MM4T

-803.55%

Dívidas
Dividendos
Cotação: $16.35

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre